Aplastic anemia
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Aplastic anemia Classification and external resources | |
| ICD-10 | D60.-D61. |
|---|---|
| ICD-9 | 284 |
| OMIM | 609135 |
| DiseasesDB | 866 |
| eMedicine | med/162 |
| MeSH | D000741 |
|
WikiDoc Resources for Aplastic anemia | |
|
Articles | |
|---|---|
|
Most recent articles on Aplastic anemia Most cited articles on Aplastic anemia | |
|
Media | |
|
Powerpoint slides on Aplastic anemia | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Aplastic anemia at Clinical Trials.gov Trial results on Aplastic anemia Clinical Trials on Aplastic anemia at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Aplastic anemia NICE Guidance on Aplastic anemia
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Aplastic anemia Discussion groups on Aplastic anemia Patient Handouts on Aplastic anemia Directions to Hospitals Treating Aplastic anemia Risk calculators and risk factors for Aplastic anemia
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Aplastic anemia | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Aplastic anemia is a condition where bone marrow does not produce sufficient new cells to replenish blood cells.
The term 'aplastic' means the marrow suffers from an aplasia that renders it unable to function properly. Anemia is the condition of having fewer red blood cells than normal, or fewer than needed to function properly. Typically, anemia refers to low red blood cell counts, but aplastic anemia patients have lower counts of all three blood cell types: red blood cells, white blood cells, and platelets.
Causes
One known cause is an autoimmune disorder, where the white blood cells attack the bone marrow.
In many cases, the etiology is impossible to determine, but aplastic anemia is sometimes associated with exposure to substances such as benzene, radiation, or to the use of certain drugs, including chloramphenicol, carbamazepine, phenytoin, quinine, and phenylbutazone. Many drugs are associated with aplasia mainly in the base of case reports but at a very low probability, As an example, chloramphenicol treatment is followed by aplasia in less than 1 in 40,000 treatment courses,and carbamazepine aplasia is even more rare.
Aplastic anaemia is present in up to 2% of patients with acute viral hepatitis.
Signs and symptoms
- Anemia with malaise, pallor and associated symptoms
- Thrombocytopenia (low platelet counts), leading to increased risk of hemorrhage and bruising
- Leukopenia (low white blood cell count), leading to increased risk of infection
Diagnosis
The diagnosis can only be made on bone marrow examination. Before this procedure is undertaken, a patient will generally have had other blood tests to find diagnostic clues, including a full blood count, renal function and electrolytes, liver enzymes, thyroid function tests, vitamin B12 and folic acid levels.
Treatment
Treating aplastic anemia involves suppression of the immune system, an effect achieved by daily medicine intake, or, in more severe cases, a bone marrow transplant, a potential cure but a risky procedure. The transplanted bone marrow replaces the failing bone marrow cells with new ones from a matching donor. The pluripotent stem cells in the bone marrow reconstitute all three blood cell lines, giving the patient a new immune system, red blood cells, and platelets. However, besides the risk of graft failure, there is also a risk that the newly created white blood cells may attack the rest of the body ("graft-versus-host disease").
Medical therapy of aplastic anemia often includes a short course of anti-thymocyte globulin (ATG or anti-lymphocyte globulin) and several months of treatment with cyclosporin to modulate the immune system. Mild chemotherapy with agents such as cyclophosphamide and vincristine may also be effective. Antibodies therapy, such as ATG, targets T-cells, which are believed to attack the bone marrow. Steroids are generally ineffective.
In the past, before the above treatments became available, patients with low leukocyte counts were often confined to a sterile room or bubble (to reduce risk of infections), as in the famed case of Ted DeVita.
Prognosis
Untreated aplastic anemia is an illness that leads to rapid death, typically within six months. If the disease is diagnosed correctly and initial treatment is begun promptly, then the survival rate for the next five to ten years is substantially improved, and many patients live well beyond that length of time.
Occasionally, milder cases of the disease resolve on their own. Relapses of previously controlled disease are, however, much more common.
Well-matched bone marrow transplants from siblings have been successful in young, otherwise healthy people, with a long-term survival rate of 80%-90%. Most successful BMT recipients eventually reach a point where they consider themselves cured for all practical purposes, although they need to be compliant with follow-up care permanently.
Older people (who are generally too frail to undergo bone marrow transplants) and people who are unable to find a good bone marrow match have five year survival rate of up to 75%.
Follow-up
Regular full blood counts are required to determine whether the patient is still in a state of remission.
10-33% of all patients develop the rare disease paroxysmal nocturnal hemoglobinuria (PNH, anemia with thrombopenia and/or thrombosis), which has been explained as an escape mechanism by the bone marrow against destruction by the immune system. Flow cytometry testing is probably warranted in all PNH patients with recurrent aplasia.
See also
External links
- Aplastic Anemia & MDS International Foundation
- Mayo Clinic
- University of Texas
- MedlinePlus Encyclopedia 000554 -- Idiopathic aplastic anemia
- MedlinePlus Encyclopedia 000529 -- Secondary aplastic anemia
- The Aplastic Anaemia Trust
- Help for Aplastic Anemia sufferers
bn:অবর্ধক রক্তশূন্যতা de:Aplastische Anämiefr:Insuffisance médullaire it:Anemia aplastica nl:Beenmergdepressie ja:再生不良性貧血fi:Aplastinen anemia sv:Aplastisk anemi
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
